Aligos Therapeutics has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts, along with methods for synthesizing them and treating diseases. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aligos Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of April 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11957683B2) discloses a compound of Formula (I) or a pharmaceutically acceptable salt thereof, with specific structural features outlined in the claims. The compound is designed for the treatment of hepatitis B and hepatitis D. The patent claims cover various configurations and substitutions within the compound, including specific arrangements for R1, R8, and R9, among others. Additionally, the patent includes a pharmaceutical composition containing the compound and an excipient for effective treatment.

Furthermore, the patent details methods for treating hepatitis B and hepatitis D in subjects by administering the compound or its salt in an effective amount. The methods also encompass the use of additional agents such as interferons, nucleoside analogs, and small molecule immunomodulators in conjunction with the compound for enhanced therapeutic outcomes. The patent aims to provide a comprehensive approach to combating hepatitis B and hepatitis D by utilizing the disclosed compound in combination with other therapeutic agents to address the specific needs of patients suffering from these conditions.

To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies